Protecting Patients With Varicose Veins

Slides:

Advertisements

Similar presentations

Setting: United Kingdom (Leeds) Target Population/Sample: Non-randomized sample of 95 patients (104 limbs) attending the venous clinic at the General Infirmary.

Advertisements

Joint Hospital Surgical Grand Round 19th October 2013

8/31/081 TREATMENT OF SMALL VEINS CHRISTI SILER, R.N. SENTARA COSMETIC AND LASER TREATMENT CENTER.

Lower Extremity Venous Disease: Peripheral Venous Insufficiency

George Sfyroeras MD, MSc, PhD, FEBVS Vascular Surgery Department Attikon University Hospital George Sfyroeras MD, MSc, PhD, FEBVS Vascular Surgery Department.

 Thrombophlebitis Kyle Christakos, David Cohee, Wade Dowling, Paul James, Levi Street, Stanton Urling.

Multimodal Management of Opioid-Induced Constipation

Addressing the Challenges in Primary and Secondary Stroke Prevention

Evaluation of the Superficial Venous System and When to Treat

New Horizons for SMA.

Clinical Trials in IBD.

This program will include a discussion of off-label treatment not approved by the FDA for use in the United States.

NOACs for Cancer-Associated Thrombosis:

Chronic Hepatitis C Virus Infection

Why New Treatments for Schizophrenia Should Be on Your Radar

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

5 Things NPs and PAs Need to Know About Tardive Dyskinesia

This talk will follow the topical structure suggested by the ABP:

Progression After Cancer Immunotherapy in Advanced NSCLC

Reducing Postoperative Ileus

Renal and Extrarenal Complications of ADPKD: Facilitating Better Patient Care.

Epidemiology Venous Pathophysiology Etiology.

Case Challenges in Chronic Migraine

Statin Selection in Special Patient Populations: A Case Challenge

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Chronic Idiopathic Urticaria

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Asthma and Atopic Comorbidities

The Evolving Role of Immunotherapy in NSCLC

Are We Closer to Personalized Medicine in MS?

New Oral Anticoagulants and VTE Management

VTE Treatment Conventional Approach

Multidisciplinary Perspectives on Interstitial Lung Diseases

Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS.

Steven T Deak, MD, PhD, FACS Deak Vein NJ Clinic Somerset, NJ

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Gene Therapy: Past, Present, and Future

Oral Anticoagulation in AF

Immunotherapy for cSCC

Perspectives on the Impact of Inflammation in OA

Impactful Data in TD That Can Guide Treatment Decisions

Introduction. Exploring Strategies for Recognition and Management of Lower Limb Spasticity in Children.

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

How to Select Therapy In Newly Diagnosed CLL

Hyperkalemia in the Hospital

Improving Outcomes in Psoriatic Arthritis

Advances in Peanut Allergy

Review of treatment for varicose veins

Scientific Update.

Guide to Atopic Dermatitis

The Burden of Psoriasis:

Patient Questions and Expert Answers in Psoriasis:

Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.

Incorporating Prostacyclins Into Practice

Program Goals Background: Anticoagulation in Patients With VTE.

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Disease Burden of VTE Phases of VTE Treatment.

5 Good Minutes on Atrial Fibrillation-related Stroke

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

A study to compare disease-specific quality of life with clinical anatomical and hemodynamic assessments in patients with varicose veins Amanda C. Shepherd,

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

PCSK9 Inhibitors and Real-World Evidence

The Real Burden of Rosacea

Foundations of Asthma.

Advances in Portopulmonary Hypertension

Motor Fluctuations in PD

Diagnosing HFpEF: What Every Cardiologist Needs to Know

Presentation transcript:

Protecting Patients With Varicose Veins

Epidemiology

Venous Pathophysiology

Etiology

Risk Factors and Screening Tips

History, Precipitating Factors, and Complications

Patient Assessment

Doppler - Direction and Velocity of Blood Flow

CEAP Classification

CEAP Classification (cont)

Venous Clinical Severity Score (VCSS)

VVSymQ™ - Patient’s point of view

Current Treatments

Catheter-based Treatments

Sclerotherapy and Sclerosing Agents

Physician-made Foam for Sclerotherapy

FDA-Approved Polidocanol Injectable Foam

VANISH-2 Efficacy

Safety Trial for Patients With PFO

Contraindications

Clinical Outcomes

Low DVT Risks of All Options

Take-Home Messages

Take-Home Messages (cont)

Abbreviations

References

References (cont)

References (cont)